NASDAQ:RLYB Rallybio (RLYB) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free RLYB Stock Alerts $1.85 +0.26 (+16.35%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$1.59▼$1.8650-Day Range$1.25▼$2.3652-Week Range$1.23▼$9.14Volume240,573 shsAverage Volume128,460 shsMarket Capitalization$69.95 millionP/E RatioN/ADividend YieldN/APrice Target$12.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Rallybio alerts: Email Address Rallybio MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside581.1% Upside$12.60 Price TargetShort InterestBearish7.43% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.45Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.60) to ($1.49) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.41 out of 5 starsMedical Sector523rd out of 938 stocksPharmaceutical Preparations Industry234th out of 417 stocks 3.4 Analyst's Opinion Consensus RatingRallybio has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.60, Rallybio has a forecasted upside of 581.1% from its current price of $1.85.Amount of Analyst CoverageRallybio has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.43% of the float of Rallybio has been sold short.Short Interest Ratio / Days to CoverRallybio has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Rallybio has recently increased by 6.67%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldRallybio does not currently pay a dividend.Dividend GrowthRallybio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RLYB. Previous Next 3.6 News and Social Media Coverage News SentimentRallybio has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Rallybio this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for RLYB on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows3 people have added Rallybio to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rallybio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.80% of the stock of Rallybio is held by insiders.Percentage Held by Institutions90.34% of the stock of Rallybio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Rallybio are expected to grow in the coming year, from ($1.60) to ($1.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rallybio is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rallybio is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRallybio has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About Rallybio Stock (NASDAQ:RLYB)Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. The company was founded in 2018 and is headquartered in New Haven, Connecticut.Read More RLYB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RLYB Stock News HeadlinesMarch 28, 2024 | americanbankingnews.comRallybio Co. (NASDAQ:RLYB) Given Average Recommendation of "Moderate Buy" by AnalystsMarch 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Rallybio on Strong Drug Pipeline and Market PotentialMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Rallybio on Promising FNAIT Treatment and Financial StabilityMarch 12, 2024 | benzinga.comRallybio: Q4 Earnings InsightsMarch 12, 2024 | finance.yahoo.comRallybio Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 26, 2024 | businesswire.comRallybio to Present at the TD Cowen 44th Annual Health Care ConferenceFebruary 7, 2024 | msn.comJefferies cuts Rallybio to hold, cites lack of near-term catalystsMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.February 7, 2024 | msn.comRallybio Announces Workforce Reduction and Restructuring CostsFebruary 7, 2024 | markets.businessinsider.comRallybio’s Strategic Focus and Strengthened Fiscal Position Garner Buy RatingFebruary 6, 2024 | markets.businessinsider.comRallybio Announces Portfolio Prioritization Plan; To Reduce Workforce By 45%February 6, 2024 | msn.comMadrigal Pharmaceuticals, Cerus among healthcare moversFebruary 6, 2024 | marketwatch.comRallybio to Cut 45% of Staff in Portfolio PrioritizationFebruary 6, 2024 | msn.comRallybio shares jump 13% on restructuring, cash runway extensionFebruary 6, 2024 | finance.yahoo.comRallybio Announces Portfolio Prioritization and Provides Corporate UpdateFebruary 2, 2024 | msn.comCanada's economy likely grew in December, avoiding recessionJanuary 6, 2024 | markets.businessinsider.comRallybio’s Drug Pipeline Promises Breakthroughs in FNAIT and gMG Treatments: Kapoor Maintains Buy RatingJanuary 4, 2024 | finance.yahoo.comRallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024December 21, 2023 | markets.businessinsider.comBuy Rating Affirmed for Rallybio on Strong Phase 1b Results and Strategic FocusDecember 20, 2023 | finance.yahoo.comRallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5December 10, 2023 | businesswire.comRallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65 th American Society of Hematology Annual MeetingDecember 9, 2023 | finance.yahoo.comRallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual MeetingNovember 29, 2023 | markets.businessinsider.comBuy Rating Affirmed for Rallybio as RLYB212 Shows Promise in FNAIT Treatment AdvancementsNovember 28, 2023 | msn.comRallybio posts early Phase 1 data for lead candidate in bleeding disorderNovember 28, 2023 | finance.yahoo.comRallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune ThrombocytopeniaNovember 25, 2023 | morningstar.comRallybio Corp RLYBSee More Headlines Receive RLYB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rallybio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/06/2023Today3/28/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RLYB CUSIPN/A CIK1739410 Webwww.rallybio.com Phone203-59-3820FaxN/AEmployees43Year FoundedN/APrice Target and Rating Average Stock Price Target$12.60 High Stock Price Target$18.00 Low Stock Price Target$8.00 Potential Upside/Downside+581.1%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-74,560,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-56.90% Return on Assets-53.38% Debt Debt-to-Equity RatioN/A Current Ratio12.39 Quick Ratio12.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.81 per share Price / Book0.66Miscellaneous Outstanding Shares37,810,000Free Float35,619,000Market Cap$69.95 million OptionableNot Optionable Beta-1.60 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Martin W. MacKay Ph.D. (Age 68)Co-Founder & Executive Chairman Comp: $707.07kDr. Stephen Uden M.B (Age 66)M.D., Co-Founder, President, CEO & Director Comp: $707.07kMr. Jonathan I. Lieber M.B.A. (Age 54)CFO & Treasurer Ms. Ami BavishiHead of Investor Relations & Corporate CommunicationsDr. Steven W. Ryder F.A.C.P (Age 72)M.D., Chief Medical Officer Key CompetitorsNextCureNASDAQ:NXTCReneo PharmaceuticalsNASDAQ:RPHMCleneNASDAQ:CLNNHomology MedicinesNASDAQ:FIXXAadi BioscienceNASDAQ:AADIView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 14,139 shares on 3/11/2024Ownership: 2.815%Goldman Sachs Group Inc.Bought 4,524 shares on 3/1/2024Ownership: 0.050%Vanguard Group Inc.Bought 14,139 shares on 2/15/2024Ownership: 2.815%Citadel Advisors LLCBought 36,506 shares on 2/15/2024Ownership: 0.843%Bridgeway Capital Management LLCBought 46,500 shares on 2/15/2024Ownership: 0.340%View All Institutional Transactions RLYB Stock Analysis - Frequently Asked Questions Should I buy or sell Rallybio stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rallybio in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RLYB shares. View RLYB analyst ratings or view top-rated stocks. What is Rallybio's stock price target for 2024? 6 equities research analysts have issued 1-year price objectives for Rallybio's stock. Their RLYB share price targets range from $8.00 to $18.00. On average, they predict the company's stock price to reach $12.60 in the next year. This suggests a possible upside of 581.1% from the stock's current price. View analysts price targets for RLYB or view top-rated stocks among Wall Street analysts. How have RLYB shares performed in 2024? Rallybio's stock was trading at $2.39 at the start of the year. Since then, RLYB stock has decreased by 22.6% and is now trading at $1.85. View the best growth stocks for 2024 here. When is Rallybio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our RLYB earnings forecast. How were Rallybio's earnings last quarter? Rallybio Co. (NASDAQ:RLYB) released its quarterly earnings results on Monday, March, 6th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.14. When did Rallybio IPO? Rallybio (RLYB) raised $80 million in an initial public offering on Thursday, July 29th 2021. The company issued 5,750,000 shares at $13.00-$15.00 per share. Who are Rallybio's major shareholders? Rallybio's stock is owned by a number of institutional and retail investors. Top institutional investors include Novo Holdings A S (4.68%), abrdn plc (4.57%), Vanguard Group Inc. (2.82%), Vanguard Group Inc. (2.82%), Blue Owl Capital Holdings LP (0.93%) and Citadel Advisors LLC (0.84%). Insiders that own company stock include Jeffrey M Fryer, Jonathan I Lieber, Kush Parmar, Martin Mackay, Opportunities I LP 5Am and Stephen Uden. View institutional ownership trends. How do I buy shares of Rallybio? Shares of RLYB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RLYB) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rallybio Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.